Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Hormonal regulation of appetite and body mass in patients with advanced prostate cancer treated with combined androgen blockade
Autore:
Nowicki, M; Bryc, W; Kokot, F;
Indirizzi:
Silesian Univ, Sch Med, Dept Nephrol Endocrinol & Metab Dis, Katowice, Poland Silesian Univ Katowice Poland Endocrinol & Metab Dis, Katowice, Poland
Titolo Testata:
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
fascicolo: 1, volume: 24, anno: 2001,
pagine: 31 - 36
SICI:
0391-4097(200101)24:1<31:HROAAB>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
SERUM LEPTIN LEVELS; NEUROPEPTIDE-Y; PLASMA LEPTIN; OBESE GENE; MEN; TESTOSTERONE; INSULIN; HYPERINSULINEMIA; ADOLESCENTS; DIFFERENCE;
Keywords:
prostate cancer; maximal androgen ablation; leptin; neuropeptide Y; insulin;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
31
Recensione:
Indirizzi per estratti:
Indirizzo: Nowicki, M Klonowa 22, PL-40168 Katowice, Poland Klonowa 22 Katowice Poland PL-40168 PL-40168 Katowice, Poland
Citazione:
M. Nowicki et al., "Hormonal regulation of appetite and body mass in patients with advanced prostate cancer treated with combined androgen blockade", J ENDOC INV, 24(1), 2001, pp. 31-36

Abstract

Cachexia is rarely observed in patients with advanced prostate cancer treated with combined androgen blockade. Androgens play an important role in the regulation of body mass composition and influence the secretion of leptin, the appetite regulating hormone. The aim of the study was to assess the influence of a combined treatment with nonsteroidal antiandrogen and LH-RH analogue on the hormonal regulation of appetite and changes in body mass in patients with advanced prostate cancer (Whitmore-Jewett stage D1 or D2). Eighteen patients with prostate cancer and 17 healthy subjects matched for age and body mass index were included. In all patients serum concentrations of leptin, neuropeptide Y (NPY), insulin, testosterone and estradiol were measured before and after four and twelve weeks of androgen blockade. Pretreatment serum leptin levels were similar in patients with prostate cancer andin the controls. In a multiple regression analysis only body mass index and testosterone significantly contributed to the variation of plasma leptin. During the treatment body mass and plasma leptin significantly increased while NPY decreased. The change of plasma NPY was significant only after 4 weeks of therapy. This study shows that the afferent regulation of leptin secretion is unchanged in advanced prostate cancer. Androgen ablation significantly increases body mass and influences secretion of appetite regulating hormones. Testosterone appears to play a significant role in the regulationof leptin secretion. (C) 2001, Editrice Kurtis.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/01/20 alle ore 06:20:38